Arun Azad
Arun Azad
Associate Professor & Medical Oncologist, Peter MacCallum Cancer Centre
Verified email at
Cited by
Cited by
ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer
AJ Armstrong, RZ Szmulewitz, DP Petrylak, J Holzbeierlein, A Villers, ...
Journal of Clinical Oncology 37 (32), 2974-2986, 2019
[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial
MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ...
The Lancet 397 (10276), 797-804, 2021
Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer
AA Azad, SV Volik, AW Wyatt, A Haegert, S Le Bihan, RH Bell, ...
Clinical cancer research 21 (10), 2315-2324, 2015
Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer
M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ...
Cancer discovery 8 (4), 444-457, 2018
Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer
AW Wyatt, AA Azad, SV Volik, M Annala, K Beja, B McConeghy, ...
JAMA oncology 2 (12), 1598-1606, 2016
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 …
DJ Khalaf, M Annala, S Taavitsainen, DL Finch, C Oja, J Vergidis, ...
The Lancet Oncology 20 (12), 1730-1739, 2019
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
JL Bishop, A Sio, A Angeles, ME Roberts, AA Azad, KN Chi, A Zoubeidi
Oncotarget 6 (1), 234, 2015
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
N Lallous, SV Volik, S Awrey, E Leblanc, R Tse, J Murillo, K Singh, ...
Genome biology 17, 1-15, 2016
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients
AA Azad, BJ Eigl, RN Murray, C Kollmannsberger, KN Chi
European urology 67 (1), 23-29, 2015
Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer
AJ Armstrong, AA Azad, T Iguchi, RZ Szmulewitz, DP Petrylak, ...
Journal of Clinical Oncology 40 (15), 1616-1622, 2022
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
N Agarwal, AA Azad, J Carles, AP Fay, N Matsubara, D Heinrich, ...
The Lancet 402 (10398), 291-303, 2023
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel
KN Chi, T Kheoh, CJ Ryan, A Molina, J Bellmunt, NJ Vogelzang, ...
Annals of Oncology 27 (3), 454-460, 2016
Continuous flow deformability‐based separation of circulating tumor cells using microfluidic ratchets
ES Park, C Jin, Q Guo, RR Ang, SP Duffy, K Matthews, A Azad, H Abdi, ...
Small 12 (14), 1909-1919, 2016
Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis
NJ Sathianathen, S Koschel, IA Thangasamy, J Teh, O Alghazo, ...
European urology 77 (3), 365-372, 2020
TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer …
MS Hofman, L Emmett, J Violet, A Y. Zhang, NJ Lawrence, M Stockler, ...
BJU international 124, 5-13, 2019
AR-V7 transcripts in whole blood RNA of patients with metastatic castration resistant prostate cancer correlate with response to abiraterone acetate
T Todenhöfer, A Azad, C Stewart, J Gao, BJ Eigl, ME Gleave, AM Joshua, ...
The Journal of urology 197 (1), 135-142, 2017
Targeting heat shock proteins in metastatic castration-resistant prostate cancer
AA Azad, A Zoubeidi, ME Gleave, KN Chi
Nature Reviews Urology 12 (1), 26-36, 2015
Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab
HK Gan, A Azad, L Cher, PLR Mitchell
Neuro-oncology 12 (2), 212-215, 2010
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in …
AJ Weickhardt, TJ Price, G Chong, V Gebski, N Pavlakis, TG Johns, ...
Journal of clinical oncology 30 (13), 1505-1512, 2012
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP …
JP Buteau, AJ Martin, L Emmett, A Iravani, S Sandhu, AM Joshua, ...
The Lancet Oncology 23 (11), 1389-1397, 2022
The system can't perform the operation now. Try again later.
Articles 1–20